Thierry Soussi

Summary

Affiliation: Institut Curie
Country: France

Publications

  1. ncbi request reprint p53 Antibodies in the sera of patients with various types of cancer: a review
    T Soussi
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, Paris, France
    Cancer Res 60:1777-88. 2000
  2. ncbi request reprint p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis
    T Soussi
    Institut Curie, UMR 218 CNRS, Paris, France
    Hum Mutat 15:105-13. 2000
  3. ncbi request reprint The p53 tumor suppressor gene: from molecular biology to clinical investigation
    T Soussi
    Institut Curie, Laboratoire de Génotoxicologie des tumeurs, Paris, France
    Ann N Y Acad Sci 910:121-37; discussion 137-9. 2000
  4. ncbi request reprint [Genetics and cancer: fundamental and clinical aspects]
    T Soussi
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, Universite P et M Curie, 26, rue d Ulm, 75005 Paris
    Cancer Radiother 5:36s-41s. 2001
  5. ncbi request reprint Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
    Thierry Soussi
    Laboratoire de Génotoxicologie des tumeurs, Departement de Pneumologie, Hopital Tenon, Paris, France
    Hum Mutat 25:6-17. 2005
  6. ncbi request reprint Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides
    Thierry Soussi
    Institut Curie and Université P and M Curie, EA3493, Laboratoire de Génotoxicologie des tumeurs, Paris, France
    Hum Mutat 21:192-200. 2003
  7. ncbi request reprint Assessing TP53 status in human tumours to evaluate clinical outcome
    T Soussi
    Institut Curie, Universite P and M Curie, Laboratoire de Génotoxicologie des tumeurs, Paris, France
    Nat Rev Cancer 1:233-40. 2001
  8. ncbi request reprint [Immunochemistry and genotype analysis of tumors. Second part: What future for the molecular diagnosis of tumors?]
    Thierry Soussi
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, Universite Pierre and Marie Curie, 26 Rue d Ulm, 75005 Paris, France
    Ann Pathol 22:113-20. 2002
  9. ncbi request reprint Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73
    Karim Bensaad
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    J Biol Chem 278:10546-55. 2003
  10. ncbi request reprint Monoclonal antibodies raised against Xenopus p53 interact with human p73
    Morgane Le Bras
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Oncogene 21:1304-8. 2002

Collaborators

Detail Information

Publications36

  1. ncbi request reprint p53 Antibodies in the sera of patients with various types of cancer: a review
    T Soussi
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, Paris, France
    Cancer Res 60:1777-88. 2000
    ..The finding of p53-Abs in the sera of individuals who are at high risk of cancer, such as exposed workers or heavy smokers, indicates that they have promising potential in the early detection of cancer...
  2. ncbi request reprint p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis
    T Soussi
    Institut Curie, UMR 218 CNRS, Paris, France
    Hum Mutat 15:105-13. 2000
    ..This software includes an optimized structure to assist and secure data entry and to allow the input of various clinical data...
  3. ncbi request reprint The p53 tumor suppressor gene: from molecular biology to clinical investigation
    T Soussi
    Institut Curie, Laboratoire de Génotoxicologie des tumeurs, Paris, France
    Ann N Y Acad Sci 910:121-37; discussion 137-9. 2000
    ..Several studies have shown that p53 mutations are associated with short survival in colorectal cancer, but the use of p53 as a tumoral marker is still a matter of debate...
  4. ncbi request reprint [Genetics and cancer: fundamental and clinical aspects]
    T Soussi
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, Universite P et M Curie, 26, rue d Ulm, 75005 Paris
    Cancer Radiother 5:36s-41s. 2001
    ..Furthermore, the relation between genotype and phenotype is not straightforward and can be influence by various parameters such as the localization of the mutation, alterations of other genes or the expression of modifiers genes...
  5. ncbi request reprint Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
    Thierry Soussi
    Laboratoire de Génotoxicologie des tumeurs, Departement de Pneumologie, Hopital Tenon, Paris, France
    Hum Mutat 25:6-17. 2005
    ....
  6. ncbi request reprint Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides
    Thierry Soussi
    Institut Curie and Université P and M Curie, EA3493, Laboratoire de Génotoxicologie des tumeurs, Paris, France
    Hum Mutat 21:192-200. 2003
    ..Overall, these data indicate that great caution is required when analyzing the significance of p53 mutations...
  7. ncbi request reprint Assessing TP53 status in human tumours to evaluate clinical outcome
    T Soussi
    Institut Curie, Universite P and M Curie, Laboratoire de Génotoxicologie des tumeurs, Paris, France
    Nat Rev Cancer 1:233-40. 2001
    ..What simple steps can be taken to ensure that patients benefit from our understanding of TP53?..
  8. ncbi request reprint [Immunochemistry and genotype analysis of tumors. Second part: What future for the molecular diagnosis of tumors?]
    Thierry Soussi
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, Universite Pierre and Marie Curie, 26 Rue d Ulm, 75005 Paris, France
    Ann Pathol 22:113-20. 2002
    ..Furthermore, the relation between genotype and phenotype is not straightforward and can be influence by various parameters such as the localization of the mutation, the alterations of other genes or the expression of modifier genes...
  9. ncbi request reprint Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73
    Karim Bensaad
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    J Biol Chem 278:10546-55. 2003
    ..These results reinforce the notion that mutant p53 with a conformational change can act as a down-regulator of the p73 pathway in human cancer and could confer a selective advantage to the tumor...
  10. ncbi request reprint Monoclonal antibodies raised against Xenopus p53 interact with human p73
    Morgane Le Bras
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Oncogene 21:1304-8. 2002
    ..Furthermore, our studies suggest that there exist specific spatial requirements for the interaction between p53 or p73 and mdm2...
  11. ncbi request reprint Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study
    Coralie Fouquet
    EA3493, UPMC IC of corrected Laboratoire de génotoxicologie des tumeurs, Paris, France
    Clin Cancer Res 10:3479-89. 2004
    ..Identifying tumor mutations in such samples will require a sensitive and robust technology to overcome signal from excess amounts of normal DNA...
  12. ncbi request reprint Locus-specific mutation databases: pitfalls and good practice based on the p53 experience
    Thierry Soussi
    Université P M Curie, 4 place Jussieu, 75005 Paris, France
    Nat Rev Cancer 6:83-90. 2006
    ..However, there are several biases in this database that can lead to serious erroneous interpretations. We describe several rules for mutation database management that could benefit the entire scientific community...
  13. ncbi request reprint Quantitative fish determination of chromosome 3 arm imbalances in lung tumors by automated image cytometry
    Khuong Truong
    Instabilité du Génome et Cancer, FRE 2584 CNRS Institut Curie and 2 IMSTAR, Paris, France
    Med Sci Monit 10:BR426-32. 2004
    ..In addition, detection of pre-neoplastic lesions with only a few cells involved may improve the diagnosis of such lesions and their precocious treatment...
  14. ncbi request reprint Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway
    Morgane Le Bras
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Oncogene 22:5082-90. 2003
    ..We also discovered that some cofactors that cooperate with p53 for apoptosis are also well conserved and belong to multigene families not detected in the human genome...
  15. ncbi request reprint Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection
    Thierry Soussi
    Laboratoire de Génotoxicologie des tumeurs, UPMC, Dpt Pneumologie, Hopital Tenon, Paris, France
    Clin Cancer Res 12:62-9. 2006
    ..We were concerned by the inclusion of dubious reports in the p53 databases that could lead to controversial analysis prejudicial to the scientific community...
  16. pmc The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
    Bernard Leroy
    Universite Pierre et Marie Curie PARIS6, 75005 Paris, France
    Nucleic Acids Res 41:D962-9. 2013
    ..For several hot spot mutants, multiple gain of function activities are also included. The database can be easily browsed via a graphical user interface...
  17. ncbi request reprint ThinPrep-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis: application to p53 mutation analysis
    Pascaline Tisserand
    Laboratoire de Génotoxicologie des tumeurs, Institut Curie, Paris, France
    Cancer 99:223-32. 2003
    ..The aim of the current study was to assess the accuracy of molecular diagnosis techniques using fine-needle sample (FNS) material stored in PreservCyt (Cytyc Corp., Boxborough, MA)...
  18. ncbi request reprint Analysis of TP53 mutation status in human cancer cell lines: a reassessment
    Bernard Leroy
    Universite Pierre et Marie Curie Paris 6, Paris, 75005, France
    Hum Mutat 35:756-65. 2014
    ..It will be updated regularly to minimize any scientific issues associated with the use of misidentified cell lines (http://p53.fr). ..
  19. ncbi request reprint TP53 mutations in human cancer: database reassessment and prospects for the next decade
    Bernard Leroy
    Universite Pierre et Marie Curie Paris 6, Paris, 75005, France
    Hum Mutat 35:672-88. 2014
    ....
  20. ncbi request reprint Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era
    Thierry Soussi
    Department of Oncology Pathology, Cancer Center Karolinska CCK, Karolinska Institute, Stockholm, Sweden Université Pierre et Marie Curie Paris 6, Paris, 75005, France
    Hum Mutat 35:766-78. 2014
    ..Based on the statistical analysis of more than 45,000 variants in the latest version of the UMD TP53 database, we also provide a classification of their functional effects ("pathogenicity"). ..
  21. ncbi request reprint Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice
    Klaus Peter Janssen
    Cellular Morphogenesis and Signalisation, UMR144, Institut Curie, Paris, France
    Gastroenterology 123:492-504. 2002
    ..Ras oncoproteins are mutated in about 50% of human colorectal cancers, but their precise role in tumor initiation or progression is still unclear...
  22. ncbi request reprint Shaping genetic alterations in human cancer: the p53 mutation paradigm
    Thierry Soussi
    Université P M Curie, 4 place Jussieu, 75005 Paris, France
    Cancer Cell 12:303-12. 2007
    ....
  23. ncbi request reprint Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination
    Hanna Berglind
    Karolinska Institute, Department of Oncology Pathology, Cancer Center Karolinska CCK, Stockholm, Sweden
    Cancer Biol Ther 7:699-708. 2008
    ..The p53 web site has been updated with new sections describing the p53 status in the majority of cell lines and a special section devoted to cell lines with controversial p53 status...
  24. ncbi request reprint The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene
    Cyril Duriez
    Unité INSERM U453, Unité d Oncologie Moléculaire, Centre Leon Berard, 28 rue Laennec, F 69373 Lyon Cedex 08, France
    Gene 282:207-14. 2002
    ..However, no mutations of BTG2/TIS21/PC3 were detected in breast cancer cells, suggesting that the inactivation of this gene is not a frequent genetic event during breast carcinogenesis...
  25. ncbi request reprint Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking
    Suleeporn Sangrajrang
    Research Division, National Cancer Institute, Rama VI Road, Ratchatewi, 10400, Bangkok, Thailand
    Lung Cancer 39:297-301. 2003
    ..1%) than in non-smokers (13.6%), though the difference was of borderline of statistical significance (P=0.061). These findings suggested that p53-Abs could be a potential biomarker for the study of individual with lung cancer...
  26. ncbi request reprint Breast-cancer stromal cells with TP53 mutations
    Cecilia Soussi Zander
    N Engl J Med 358:1635; author reply 1636. 2008
  27. ncbi request reprint Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors
    Zhi Ping Ren
    Department of Genetics and Pathology, Uppsala University, University Hospital, Uppsala, Sweden
    J Neuropathol Exp Neurol 66:944-54. 2007
    ..Our results are of importance for a further understanding of the molecular mechanisms behind failure to treat glioma patients...
  28. ncbi request reprint MUT-TP53: a versatile matrix for TP53 mutation verification and publication
    Thierry Soussi
    Hum Mutat 27:1151-4. 2006
  29. ncbi request reprint Focus on the p53 gene and cancer: advances in TP53 mutation research
    Thierry Soussi
    Hum Mutat 21:173-5. 2003
  30. ncbi request reprint The UMD-p53 database: new mutations and analysis tools
    Christophe Beroud
    Laboratoire de Genetique Moleculaire, CHU de Montpellier, Institut Universitaire de Recherche Clinique, Montpellier Cedex, France
    Hum Mutat 21:176-81. 2003
    ..To achieve theses purposes we have designed a procedure to check and validate data in order to reach the highest quality data...
  31. ncbi request reprint The UMD TP53 database and website: update and revisions
    Dalil Hamroun
    Laboratoire de Génétique Moleculaire et Chromosomique, Institut Universitaire de Recherche Clinique et CHU, CNRS UPR 1142, Montpellier, France
    Hum Mutat 27:14-20. 2006
    ..umd.be:2072/) that will generate a detailed informative page for every TP53 mutant in the database. New tools to check TP53 mutations and minimize errors found in the literature are also available...
  32. ncbi request reprint UMD (Universal Mutation Database): 2005 update
    Christophe Beroud
    Laboratoire de Genetique Moleculaire, IURC, Montpellier, France
    Hum Mutat 26:184-91. 2005
    ....
  33. ncbi request reprint p53 mutations and resistance to chemotherapy: A stab in the back for p73
    Thierry Soussi
    Cancer Cell 3:303-5. 2003
    ..p73 is essential for apoptosis induced by many cytotoxic agents, but this function can be blocked by a particular category of p53 mutations that have consequently acquired a gain of function...
  34. ncbi request reprint [p53 mutations and resistance to chemotherapy: a stab in the back for p73?]
    Thierry Soussi
    Bull Cancer 90:383-6. 2003
    ..Such discovery will be important for a better understanding of the signaling pathway that lead to resistance to chemotherapy...
  35. ncbi request reprint Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors
    Reyna Favis
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, USA
    Hum Mutat 24:63-75. 2004
    ..Data analysis comparing colon cancer entries in the TP53 database (http://p53.curie.fr) with the results reported in this study showed that distribution of mutations and the mutational events were comparable...
  36. ncbi request reprint Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors
    Pascaline Tisserand
    Laboratoire de Genotoxicololgie des Tumeurs Paris, France
    Cancer Biol Ther 2:559-63. 2003
    ..Medullary carcinoma of the breast should therefore be considered to be a unique entity defined by specific histologic and molecular traits...